News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProSensa B.V. and GlaxoSmithKline (GSK) Initiate Development of Four Additional Products Under Existing Alliance in Duchenne Muscular Dystrophy



6/23/2010 6:48:51 AM

LEIDEN, Netherlands--(BUSINESS WIRE)--Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of both the potential of Prosensa’s “exon skipping” platform and the ongoing relationship.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES